Striving to transform the treatment of disease by harnessing the power of cell therapy

At the cutting edge of science, cell therapy... the next frontier

We are a clinical stage cell therapy company that approaches science like an artist approaches a blank canvas: with creativity, passion and a desire to create something with lasting impact.

We are investigating the potential of cell therapy to replace cells that are damaged or lost to disease in order to create medicines in a new way.


Read More about:
Press Releases | Announcement

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Read More about:
Press Releases | Announcement

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

Read More about:
Press Releases | Announcement

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics

Creating next-generation medicines for patients in need

Replace damaged cells

Restore function

Reimagine what can be possible with cellular medicine

The Courage to Ask, “What If?”

At BlueRock, we’re driven to transform the treatment of degenerative diseases, to turn “What if?” into “Here’s how.”

Learn about the science of BlueRock

Question everything.

BlueRockers are driven by the relentless pursuit of an audacious goal—to transform the way degenerative diseases are treated.

Learn about life at BlueRock

BlueRock Therapeutics scientist in googles working in lab

Cutting edge science.
A world of potential.

We strive to evolve the treatment of disease, moving away from traditional treatment options to investigating the replacement of cells damaged or lost to disease—starting with Parkinson’s disease.

Learn more about our programs in clinical development.


This field is for validation purposes and should be left unchanged.